Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a potent endothelial cell mitogen which mediates its effects by binding to tyrosine kinase receptors. We have characterized the VEGF-activated intracellular signal transduction pathway in bovine aortic endothelial cells and correlated this to its mitogenic effects. VEGF induced concentration- and time-dependent increases in protein kinase C (PKC) activation with a maximum of 2.2-fold above the basal level at 5 x 10(-10) M within 10 min as measured both by in situ and translocation assays. Immunoblotting analysis of PKC isoforms in cytosolic and membrane fractions indicated that after VEGF stimulation the content of Ca(2+)-sensitive PKC isoforms (alpha and betaII) was increased in the membrane fractions, whereas no changes were observed for PKC isoforms delta and epsilon. The stimulation of PKC activity by VEGF was preceded by the activation of phospholipase Cgamma (PLCgamma). This was demonstrated by parallel increases in PLCgamma tyrosine phosphorylation, [3H]inositol phosphate production, and [3H]arachidonic acid-labeled diacylglycerol formation in bovine aortic endothelial cells. In addition, VEGF increased phosphatidylinositol 3-kinase activity 2.1-fold which was inhibited by wortmannin, a phosphatidylinositol 3-kinase inhibitor, without decreasing the VEGF-induced increase in PKC activity or endothelial cell growth. Interestingly, genistein, a tyrosine kinase inhibitor, and GFX or H-7, PKC inhibitors, abolished both VEGF-induced PKC activation and endothelial cell proliferation. VEGF's mitogenic effect was inhibited by a PKC isoform beta-selective inhibitor, LY333531, in a concentration-dependent manner. In contrast, antisense PKC-alpha oligonucleotides enhanced VEGF-stimulated cell growth with a simultaneous decrease of 70% in PKC-alpha protein content. Thus, VEGF appears to mediate its mitogenic effects partly through the activation of the PLCgamma and PKC pathway, involving predominately PKC-beta isoform activation in endothelial cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, within the TME, PKC beta, another PKC isoform, is a well‐documented effector of the VEGF signaling that promotes angiogenesis and is required for invasiveness in certain tumors, such as pancreatic tumors [122, 123, 124].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [122]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · cited 2×
“and assayed by the method of Bradford (19).”
MethodInfluentialA RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751 · cited 1×
“The cells were scraped and total lipids were extracted with chloroform according to the methods of Bligh and Dyer (22).”
MethodVascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 2×
“VEGF was independently isolated as both an endothelial cell growth factor (1) and as a vasopermeability factor (3).”
BackgroundVascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Intracellular Signaling by Hydrolysis of Phospholipids and Activation of Protein Kinase C
Nishizuka, Y. (1992) · Science · doi:10.1126/science.1411571 · Cited by 4,472 · cited 4×
“In contrast, PKC isoforms e and d, which lack Ca(21) binding sites, are only responsive to DAG and did not translocate adequately for our antibodies to detect (25).”
BackgroundMethodInfluentialAiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793 · cited 2×
“Physiologically, elevated levels of VEGF have been associated with tumor angiogenesis (7) and hypoxia-induced proliferative ocular disorders such as diabetic proliferative retinopathy and retinal vein occlusion (8, 9).”
BackgroundSelf-citationGenistein, a specific inhibitor of tyrosine-specific protein kinases.
Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., & Fukami, Y. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45614-1 · Cited by 3,724 · cited 1×
“The addition of genistein (40 mm), a tyrosine kinase inhibitor (27), significantly reduced the VEGF-induced tyrosine phosphorylation of PLCg.”
BackgroundOncogenes and signal transduction
Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R., & Soltoff, S. (1991) · Cell · doi:10.1016/0092-8674(91)90639-g · Cited by 2,694 · cited 2×
“Since PI 3-kinase has been shown to be associated with several different tyrosine kinase receptors (29), and VEGF has been reported to increase PI 3-kinase tyrosine phosphorylation (12, 13), we determined whether PI 3-kinase activity could also be activated by VEGF.”
BackgroundThe bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C
Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., & Loriolle, F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98476-0 · Cited by 2,456
Plate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992) · Nature · doi:10.1038/359845a0 · Cited by 2,275 · cited 1×
“Physiologically, elevated levels of VEGF have been associated with tumor angiogenesis (7) and hypoxia-induced proliferative ocular disorders such as diabetic proliferative retinopathy and retinal vein occlusion (8, 9).”
Background
Cited by
Items 201–300 of 615
The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy
Curtis, T. M., & Scholfield, C. N. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.431 · Cited by 74
Spyridopoulos, I., Luedemann, C., Chen, D., Kearney, M., Chen, D., Murohara, T., Principe, N., Isner, J. M., & Losordo, D. W. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000020006.89055.11 · Cited by 74
Gingras, D., Lamy, S., & Béliveau, R. (2000) · Biochemical Journal · doi:10.1042/bj3480273 · Cited by 74
Redox balance dynamically regulates vascular growth and remodeling
Bir, S. C., Kolluru, G. K., Fang, K., & Kevil, C. G. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.05.003 · Cited by 68
Wang, L., Xing, X., Holmes, A. S., Wadham, C., Gamble, J. R., Vadas, M. A., & Xia, P. (2005) · Circulation Research · doi:10.1161/01.res.0000187469.82595.15 · Cited by 72
Self-citationSpeyer, C. L., Hachem, A. H., Assi, A. A., Johnson, J. S., DeVries, J. A., & Gorski, D. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088830 · Cited by 71
“Of the downstream mediators of VEGF receptors, PKC is known to be a crucial mediator [12,13].”
BackgroundPrediction of diabetic retinopathy: role of oxidative stress and relevance of apoptotic biomarkers
Al‐Shabrawey, M., & Smith, S. B. (2010) · The EPMA Journal · doi:10.1007/s13167-010-0002-9 · Cited by 73
“ptosis, and regulating the action of VEGF [58–60].”
BackgroundSun, J., Xu, Y., Sun, S., Sun, Y., & Wang, X. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0495-5 · Cited by 71
“HRECs were isolated as previously described [16].”
Agrawal, S. S., Naqvi, S., Gupta, S. K., & Srivastava, S. (2012) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.05.057 · Cited by 71
“…protein glycation as seen in hemoglobin A1C (Brownlee et al., 1984); Protein Kinase-C activation which may lead to enhanced permeability of retinal vasculature, basement membrane thickening and cellular signaling by vascular endothelial growth factors (VEGF) (Xia et al., 1996; Miller et al., 1997).”
BackgroundCho, C., Lee, C. S., Chang, M. V., Jang, I. H., Kim, S. J., Hwang, I., Ryu, S. H., Lee, C. O., & Koh, G. Y. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00786.2003 · Cited by 71
“On activation of VEGFR-2 in endothelial cells, three major second messenger pathways elicit cell proliferation, migration, and survival, which are essential steps for angiogenesis (10, 14, 18, 21, 22, 28, 38, 39, 41, 42).”
BackgroundThe role of protein kinase C in the development of the complications of diabetes
Ways, D. K., & Sheetz, M. J. (2000) · Vitamins and hormones · doi:10.1016/s0083-6729(00)60019-5 · Cited by 74
Wu, J., Stratford, A. L., Astanehe, A., & Dunn, S. E. (2007) · PubMed Central · Cited by 70
Jesmin, S., Hattori, Y., Sakuma, I., Liu, M., Mowa, C. N., & Kitabatake, A. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200302000-00005 · Cited by 69
Itoh, S., Brawley, L., Wheeler, T., Anthony, F. W., Poston, L., & Hanson, M. A. (2002) · Pediatric Research · doi:10.1203/00006450-200204000-00014 · Cited by 69
“Experiments were also conducted to determine whether any effect on the response to VEGF was dependent on reduction of NO or PGI2 production.”
BackgroundInfluentialExpression of Thrombospondin-1 in Ischemia-Induced Retinal Neovascularization
Suzuma, K., Takagi, H., Otani, A., Oh, H., & Honda, Y. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65281-9 · Cited by 69
Self-citationWang, Y., Pampou, S., Fujikawa, K., & Varticovski, L. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10386 · Cited by 69
“Activation of PKC has been proposed to be involved in VEGF-induced vascular permeability and proliferation of endothelial cells (Xia et al., 1996; Bates et al., 1999; Yoshiji et al., 1999).”
BackgroundDiabetic vascular dysfunction: Links to glucose‐induced reductive stress and VEGF
Tilton, R. G. (2002) · Microscopy Research and Technique · doi:10.1002/jemt.10092 · Cited by 70
“In addition, both diabetes- and VEGF-induced hyperpermeability changes in rat retinas can be blocked by LY333531 (Aiello et al., 1997; Ishii et al., 1996) and glucose-induced expression of VEGF in tissue culture can be blocked with PKC inhibitors (Williams et al., 1997).”
Holmes, D. I. R., & Zachary, I. C. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.11.009 · Cited by 67
Src, Fyn and Yes play differential roles in VEGF-mediated endothelial cell events
Werdich, X. Q., & Penn, J. S. (2006) · Angiogenesis · doi:10.1007/s10456-005-9021-x · Cited by 67
“Upon VEGF stimulation, SFKs function upstream of PLC-c, which eventually leads to the activation of Raf-MEKERK pathway and induces cell proliferation [18, 41, 42].”
BackgroundScoditti, E., Massaro, M., Carluccio, M. A., Distante, A., Storelli, C., & Caterina, R. D. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp400 · Cited by 66
Capellini, V. K., Celotto, A. C., Baldo, C. F., Olivon, V. C., Viaro, F., Rodrigues, A. J., & Évora, P. R. B. (2010) · Current Vascular Pharmacology · doi:10.2174/157016110791330834 · Cited by 68
Kaneko, Y., Kitazato, K., & Basaki, Y. (2003) · Journal of Cell Science · doi:10.1242/jcs.00871 · Cited by 67
“The endothelial cell-specific mitogen, vascular endothelial growth factor (VEGF), has been shown to induce PI 3-kinase activity in a variety of endothelial cells and to be a key positive regulator of angiogenesis (Guo et al., 1995; Xia et al., 1996; Kevil et al., 1998).”
BackgroundRole of PLCγ and Ca2+in VEGF- and FGF-induced choroidal endothelial cell proliferation
McLaughlin, A. P., & Vries, G. W. D. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.281.5.c1448 · Cited by 66
Maeno, Y., Li, Q., Park, K., Rask‐Madsen, C., Gao, B., Matsumoto, M., Liu, Y., Wu, I., White, M. F., Feener, E. P., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.286591 · Cited by 65
“It is also likely that activation of other PKC isoforms may even enhance VEGF action and angiogenesis (37).”
BackgroundSelf-citationKumar, B., Gupta, S. K., Srinivasan, B. P., Nag, T. C., Srivastava, S., & Saxena, R. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2012.02.007 · Cited by 65
Joy, S. V., Scates, A. C., Bearelly, S., Dar, M. S., Taulien, C. A., Goebel, J. A., & Cooney, M. J. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e572 · Cited by 65
Rajesh, M., Kolmakova, A., & Chatterjee, S. B. (2005) · Circulation Research · doi:10.1161/01.res.0000185327.45463.a8 · Cited by 65
Vascular Dysfunction in Hyperglycemia: Is Protein Kinase C the Culprit?
Gutterman, D. D. (2002) · Circulation Research · doi:10.1161/res.90.1.5 · Cited by 65
The Calcium Signaling Mechanisms in Arterial Smooth Muscle and Endothelial Cells
Ottolini, M., & Sonkusare, S. K. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200030 · Cited by 64
Abid, M. R., Shih, S., Otu, H. H., Spokes, K., Okada, Y., Curiel, D. T., Minami, T., & Aird, W. C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608620200 · Cited by 63
Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research
Donnelly, R., Idris, I., & Forrester, J. V. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.88.1.145 · Cited by 63
“22 Thus, activation of PKC-b seems to be an essential step in VEGF mediated endothelial cell migration and replication (early steps in angiogenesis).”
BackgroundEtiologic Mechanisms in Diabetic Retinopathy
Frank, R. N. (2006) · Elsevier eBooks · doi:10.1016/b978-0-323-02598-0.50072-0 · Cited by 65
Normalization of retinal vascular permeability in experimental diabetes with genistein.
Nakajima, M., Cooney, M. J., Tu, A. H., Chang, K. Y., Cao, J., Ando, A., An, G.-J., Melia, M. B., & de Juan, E. (2001) · PubMed · Cited by 63
List, A. F., Glinsmann‐Gibson, B., Stadheim, C., Meuillet, E. J., Bellamy, W. T., & Powis, G. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.03.005 · Cited by 63
Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor
Saijonmaa, O. J., Nyman, T., Kosonen, R., & Fyhrquist, F. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.280.2.h885 · Cited by 63
“VEGF has been reported to activate PKC in endothelial cells, an effect that was abolished by the PKC inhibitors GFX and H-7 (31).”
BackgroundMason, J. C., Lidington, E. A., Yarwood, H., Lublin, D. M., & Haskard, D. O. (2001) · Arthritis & Rheumatism · Cited by 61
Ruboxistaurin: PKC-β inhibition for complications of diabetes
Danis, R. P., & Sheetz, M. J. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903401620 · Cited by 60
“There are clearly direct effects of VEGF on endothelial cells transduced via PKC-b that can be blocked by RBX [40], although these results do not preclude the possibility that permeability is also regulated by other mechanisms or via PKC in other cell types [9].”
BackgroundTeicher, B. A., Menon, K., Álvarez, E., Galbreath, E. J., Shih, C., & Faul, M. M. (2001) · PubMed · Cited by 60
Diabetic Retinopathy: Important Biochemical Alterations and the Main Treatment Strategies
Valdez-Guerrero, A. S., Quintana-Pérez, J. C., Arellano-Mendoza, M. G., Ibarra, F. C., Cach, F. T., & Alemán-González-Duhart, D. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.10.009 · Cited by 59
Human Genetics of Diabetic Retinopathy: Current Perspectives
Ng, D. P. K. (2010) · Journal of Ophthalmology · doi:10.1155/2010/172593 · Cited by 59
“Regulation of target genes such as heptocyte growth factor (HGF), urinary and tissue plasminogen activator (uPA, tPA), matrix metalloproteinase9 (MMP9) is then achieved through complex signaling pathways, including through protein kinase C (PKC) [37].”
BackgroundBernatchez, P. N., Allen, B. G., Gélinas, D. S., Guillemette, G., & Sirois, M. G. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704367 · Cited by 59
“The incomplete suppression of PAF synthesis by Genistein may result from its lack of selectivity since Genistein has previously been shown to block partially the intracellular phosphorylation cascade elicited by a VEGF treatment (Xia et al., 1996).”
BackgroundMason, J. C., Lidington, E. A., Ahmad, S. R., & Haskard, D. O. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00339.2001 · Cited by 59
“In contrast, the effects of VEGF on EC DAF expression and proliferation are both PKC dependent (24, 52).”
BackgroundThe effects of interleukin-7 on the lymphangiogenic properties of human endothelial cells
Al-Rawi, M. A. A., Watkins, G., Mansel, R. E., & Jiang, W. G. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.3.721 · Cited by 58
Kružliak, P., Kovacova, G., & Pecháňová, O. (2012) · Angiogenesis · doi:10.1007/s10456-012-9327-4 · Cited by 58
“IP3 induces the influx of calcium [38, 39].”
Young, T. A., Wang, H., Munk, S., Hammoudi, D. S., Young, D. S., Mandelcorn, M. S., & Whiteside, C. I. (2005) · Experimental Eye Research · doi:10.1016/j.exer.2004.11.015 · Cited by 57
Reihill, J. A., Ewart, M., & Salt, I. P. (2011) · Vascular Cell · doi:10.1186/2045-824x-3-9 · Cited by 57
“Phosphorylation of eNOS at Ser1177 is not the only mechanism by which VEGF acts to stimulate nitric oxide synthesis, as VEGF has been demonstrated to stimulate PLCg-mediated increases in intracellular Ca [30,31], which act to directly stimulate eNOS independent of phosphorylation.”
Hu, W., Criswell, M. H., Fong, S., Temm, C. J., Gangaraju, R., Cornell, T. L., & Clauss, M. A. (2008) · Experimental Eye Research · doi:10.1016/j.exer.2008.10.014 · Cited by 56
“VEGF also can activate PKC, MAPK, and PI3K pathways (Xia et al., 1996).”
BackgroundPhosphodiesterase Inhibitor-mediated Potentiation of Adenovirus Delivery to Myocardium
Nagata, K., Marbán, E., Lawrence, J. H., & Donahue, K. (2001) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2000.1322 · Cited by 56
Mason, J. C., Steinberg, R., Lidington, E. A., Kinderlerer, A. R., Ohba, M., & Haskard, D. O. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407981200 · Cited by 56
Rademaker-Lakhai, J. M., Beerepoot, L. V., Mehra, N., Radema, S. A., van Maanen, R. J., Vermaat, J. S. P., Witteveen, E. O., Visseren‐Grul, C., Musib, L. C., Enas, N. H., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2912 · Cited by 56
The therapeutic role of targeting protein kinase C in solid and hematologic malignancies
Podar, K., Raab, M. S., Chauhan, D., & Anderson, K. C. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.10.1693 · Cited by 56
“In addition to their direct effects on tumor cells, PKC and PKCβ signaling pathways are also linked to VEGF- and 12O -tetradecanoylphorbol 13-acetate-triggered angiogenesis [80-85] .”
BackgroundSydorova, M., & Lee, M. S. (2005) · Ophthalmic Research · doi:10.1159/000086594 · Cited by 55
“they aim to interrupt any proangiogenic growth factors and downregulate their signal, decrease endogenous or exogenous inhibitors and focus mainly on neovasculature. For instance, protein kinase C-β inhibitor is able to stop VEGF-induced retinal endothelial cell growth [”
BackgroundAl-Rawi, M. A. A., Watkins, G., Mansel, R. E., & Jiang, W. G. (2005) · British journal of surgery · doi:10.1002/bjs.4832 · Cited by 55
Shen, B., Lee, D. Y., Cortopassi, K. M., Damico, L. A., & Zioncheck, T. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007969200 · Cited by 54
Andrikopoulos, P., Eccles, S. A., & Yaqoob, M. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.05.013 · Cited by 53
Chen, Y., & LaCasce, A. S. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.6.939 · Cited by 53
“Drugs (2008) 17(6) PKCβ participates in vascular endothelial growth factor (VEGF) signaling [10,11] , regulates progression through the cell cycle, and communicates with the phosphoinositide-3 kinase/AKT (PI3K/AKT) pathway, which regulates apoptosis [12] .”
BackgroundProtein kinase C β inhibition: a novel therapeutic strategy for diabetic microangiopathy
IDRIS, I. R., & Donnelly, R. (2006) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2006.026 · Cited by 53
Zinc Dynamics in the Myocardial Redox Signaling Network
Korichneva, I. L. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.1707 · Cited by 53
JIA, L., Wang, C., Zhao, S., Lü, X., & Xu, G. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2007.10.033 · Cited by 52
Hernández, C., & Simó, R. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.8.1209 · Cited by 52
“VEGF can activate several PKC isoforms, including α , β 1, β 2 and δ isoforms [47,48] .”
BackgroundMethodCheng, L., Jia, H., Löhr, M., Bagherzadeh, A., Holmes, D. I. R., Selwood, D., & Zachary, I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402488200 · Cited by 47
Handa, A., Gotoh, M., Hamada, K., Yanagisawa, K., Yamazaki, H., Nakamura, M., Ueyama, Y., Mochida, J., & Fukuda, H. (2003) · Journal of Orthopaedic Research® · doi:10.1016/s0736-0266(03)00102-5 · Cited by 51
Diabetic macular edema: classification, medical and laser therapy
Bandello, F. M., Pognuz, D. R., Polito, A., Pirracchio, A., Menchini, F., & Ambesi–Impiombato, M. (2003) · Seminars in Ophthalmology · doi:10.1080/08820530390895262 · Cited by 51
“Moreover, PKC has been shown to be an integral component of cellular signaling induced by the vascular endothelial growth factor (VEGF).(12) VEGF is a potent cytokine that induces changes in the structure of the tight junctions that leads to the increase of vascular permeability.”
Xu, Z., Yu, Y., & Duh, E. J. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-1528 · Cited by 51
“Our results also indicate a particularly important role in ADAMTS1 stimulation for the PKC isoform, which has previously been shown to play a major role in VEGF-induced endothelial cell proliferation.(32) In contrast, we found that the upregulation of ADAMTS1 expression by VEGF was independent of the MEK/ ERK pathway.”
ResultExpression of adhesion molecules by sphingosine 1-phosphate and histamine in endothelial cells
Shimamura, K., Takashiro, Y., Akiyama, N., Hirabayashi, T., & Murayama, T. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.12.022 · Cited by 50
Wu, J., & Sheibani, N. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10600 · Cited by 50
“…factor, stimulates proliferation, migration, and barrier dysfunction of endothelial cells through activation of multiple signal transduction pathways that vary depending on EC origin [Xia et al., 1996; Kroll and Waltenberger, 1997; Esser et al., 1998; Cohen et al., 1999; Yashima et al., 2001].”
BackgroundProtein Kinase C-β as a Therapeutic Target in Breast Cancer
SLEDGEJR, G., & Gökmen‐Polar, Y. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.03.019 · Cited by 50
Wong, E. Y. M., Morgan, L., Smales, C., Lang, P., Gubby, S. E., & Staddon, J. M. (2000) · Biochemical Journal · doi:10.1042/bj3460209 · Cited by 50
Protein Kinase C Mediates the Mitogenic Action of Thrombopoietin in c-Mpl–Expressing UT-7 Cells
Hong, Y., Dumènil, D., van der Loo, B., Goncalves, F., Vainchenker, W., & Erusalimsky, J. D. (1998) · Blood · doi:10.1182/blood.v91.3.813 · Cited by 50
Teicher, B. A., Menon, K., Álvarez, E., Shih, C., & Faul, M. M. (2002) · Investigational New Drugs · doi:10.1023/a:1016297611825 · Cited by 50
“The acyclic bisindolylmaleimide 317615 . 2HCl is a potent and selective inhibitor of protein kinase Cβ (Figure 1). In cell culture, the compound 317615 . 2HCl was a more potent inhibitor of VEGF-stimulated HUVEC proliferation (IC50 = 150 nM, 72h) then of human SW2 small cell lung carcinoma cell proliferation (IC50 =3…”
BackgroundWang, D., Wang, L., Gu, J., Yang, H., Liu, N., Lin, Y., Li, X., & Shao, C. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000109 · Cited by 51
“HRECs were obtained from ScienCell Research Laboratories and cultured as previously described.(17) Briefly, cells were grown in human endothelial serum-free medium (SFM) (Gibco, Grand Island, NY) supplemented with 10% fetal calf serum (PAA, Co, Pittsburgh, PA), penicillin (100 U/mL), streptomycin (100 U/mL), and endot…”
MethodAlnahdi, A., John, A., & Raza, H. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495200 · Cited by 49
Emerging roles of PLCγ1 in endothelial biology
Chen, D., & Simons, M. (2021) · Science Signaling · doi:10.1126/scisignal.abc6612 · Cited by 49
“Unlike phorbol esters, which activate DAG-sensitive PKCs and induce a translocation of PKC, PKC, and PKC from the cytosol to the juxtamembrane region (129, 140), VEGF stimulation induces translocation of only PKC, suggesting that this PKC isoform specifically responds to VEGF signaling (66).”
BackgroundMa, S., & Rosen, S. T. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f10a00 · Cited by 49
The Role of Protein Kinase C Activation in the Pathogenesis of Diabetic Vascular Complications
Park, J. Y., Ha, S. W., & King, G. L. (1999) · Peritoneal Dialysis International · doi:10.1177/089686089901902s37 · Cited by 48
“VEGF/VPF is mediating its mitogenic and permeabilityinducing actions by activating PKC β-isoform through tyrosine phosphorylation ofPLC (28).”
BackgroundSelf-citationRegulation of cdk2 Activity in Endothelial Cells That Are Inhibited From Growth by Cell Contact
Chen, D., Walsh, K. X., & Wang, J. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.3.629 · Cited by 48
Novel therapeutic agents for B-cell lymphoma: developing rational combinations
Reeder, C. B., & Ansell, S. M. (2010) · Blood · doi:10.1182/blood-2010-06-255067 · Cited by 47
Lymphangiogenesis and its role in cancer.
Al-Rawi, M. A. A., Mansel, R. E., & Jiang, W. G. (2005) · PubMed · doi:10.14670/hh-20.283 · Cited by 47
Odia, Y., IWAMOTO, F. M., Moustakas, A., Fraum, T. J., Salgado, C. A., Li, A., Kreisl, T. N., Sul, J., Butman, J. A., & Fine, H. A. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-2020-x · Cited by 46
Caron, C., Spring, K., Laramée, M., Chabot, C., Cloutier, M., Gu, H., & Royal, I. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.02.004 · Cited by 46
Vasculogenensis, angiogenesis and special features of tumor blood vessels
Hiratsuka, S. (2010) · Frontiers in bioscience · doi:10.2741/3796 · Cited by 46
Haemodynamics in microvascular complications in type 1 diabetes
Candido, R., & Allen, T. J. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.313 · Cited by 46
“Furthermore, VEGF leads to PKC activation via the VEGF-R2, increasing DAG and IP3 levels [203].”
BackgroundAlden, K. J., Goldspink, P. H., Ruch, S. W., Buttrick, P. M., & García, J. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00494.2001 · Cited by 46
“LY-379196 (30 nM) was also maintained in the extracellular recording solution as described previously (9, 10, 21).”
BackgroundMethodGao, R. B., Zhu, B., Tang, S., Wang, J., & Ren, J. T. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00797.x · Cited by 45
Ben-Mahmud, B. M., Mann, G. E., Datti, A., Orlacchio, A., KOHNER, E. M., & Chibber, R. (2004) · Diabetes · doi:10.2337/diabetes.53.11.2968 · Cited by 45
Role of PKCδ in Insulin Sensitivity and Skeletal Muscle Metabolism
Li, M., Vienberg, S. G., Bezy, O., O’Neill, B. T., & Kahn, C. R. (2015) · Diabetes · doi:10.2337/db14-1891 · Cited by 40
“PKCd is a member of the novel family of PKC proteins and is involved in many pathological conditions, including ischemic heart disease (10,11) and cancer (12).”
BackgroundNoma, H., Funatsu, H., Mimura, T., Eguchi, S., & Hori, S. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.04.006 · Cited by 44
Lymphangiogenesis and cancer metastasis
Mahir, A. A.-R. (2010) · Frontiers in bioscience · doi:10.2741/3715 · Cited by 44
“of phosphoinositol-3 kinase (PI3-K) in both endothelial and cancer cells (69, 70).”
BackgroundHerbst, R. S., Oh, Y. W., Wagle, A., & Lahn, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0538 · Cited by 44
Villard, E., Alonso, A., Agrapart, M., Challah, M., & Soubrier, F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.39.25191 · Cited by 44
Molecular biology of choroidal neovascularization.
Lu, M., & Adamis, A. P. (2006) · PubMed · doi:10.1016/j.ohc.2006.05.001 · Cited by 43
Distinct signaling pathways confer different vascular responses to VEGF 121 and VEGF 165
Zhang, Y., Zhang, Y., Furumura, M., Zhang, Y., Furumura, M., & Morita, E. (2008) · Growth Factors · doi:10.1080/08977190802105909 · Cited by 43
“In this light, activation of phospholipase C results in protein kinase C (PKC) activation, and PKC-mediated activation of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) cascade in turn mediates VEGF-induced endothelial cell proliferation (Xia et al. 1996; Takahashi et al.…”
BackgroundDull, R. O., Yuan, J., Chang, Y. S., Tarbell, J. M., Jain, R. K., & Munn, L. L. (2001) · Microvascular Research · doi:10.1006/mvre.2000.2298 · Cited by 42
Vascular endothelial growth factor in diabetes induced early retinal abnormalities
Cukiernik, M., Hileeto, D., Evans, T., Mukherjee, S., Downey, D. B., & Chakrabarti, S. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.02.002 · Cited by 42
Cai, R., Li, C., Zhao, Y., Yuan, H., Zhang, X., Liang, A., & Yi, Y. (2025) · Chinese Medicine · doi:10.1186/s13020-025-01150-w · Cited by 43
“PKC also affects angiotensin-II-mediated vasoregulation, causing glomerular hyperfiltration, and influences vascular permeability and neovascularization by regulating vascular endothelial growth factor (VEGF) expression, thereby accelerating proteinuria progression [28–30].”
Budhiraja, S., & Singh, J. (2008) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00583.x · Cited by 41
Zhang, X., Wen, L., Yan-jiong, C. H. E. N., & Zhu, Y. (2009) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.2009.03.019 · Cited by 41
Clauss, M. A., & Breier, G. (2005) · Birkhäuser Basel eBooks · doi:10.1007/b137088 · Cited by 41
Vascular endothelial growth factor gene regulation and action in diabetic retinopathy
LU, M., & ADAMIS, A. (2002) · Ophthalmology Clinics of North America · doi:10.1016/s0896-1549(01)00010-4 · Cited by 41
“VEGF receptors on endothelial cells appear to be tyrosine kinases capable of phosphorylating other proteins involved in cellular signal transduction [111].”
BackgroundScutellarin promotes in vitro angiogenesis in human umbilical vein endothelial cells
Gao, Z., Huang, D., Li, H., Zhang, L.-N., Lv, Y., Cui, H., & Zheng, J. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.08.034 · Cited by 40
Metadata
- Authors
- Xia, P., Aiello, L. P., Ishii, H., Jiang, Z. Y., Park, D. J., Robinson, G. S., Takagi, H., Newsome, W. P., Jirousek, M. R., & King, G. L.
- Affiliations
- Joslin Diabetes Center (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Eli Lilly (United States) (US)
- Venue
- Journal of Clinical Investigation
- Published
- 1996-11-01
- Volume
- 98
- Issue
- 9
- Pages
- 2018-2026
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC507645
- OpenAlex
- W2075553837
- Cited by
- 566
- References
- 39
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 3 · 2017: 3 · 2016: 9 · 2015: 8 · 2014: 14 · 2013: 21 · 2012: 19
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (5r01dk036433-10, 5r29ey010827-04, 5r01ey005110-18, EY05110)
- National Eye Institute (EY10827, EY05110)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK36433)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- vascular endothelial growth factor, protein kinase C, PKC isoforms, PKC beta, endothelial cell proliferation, signal transduction, phospholipase C-gamma, phosphatidylinositol 3-kinase, diacylglycerol, ruboxistaurin, genistein, wortmannin, bovine aortic endothelial cells
- MeSH terms
- Animals, Cattle, Cell Division, Diglycerides, Endothelium, Vascular, Enzyme Activation, Inositol Phosphates, Isoenzymes, Lymphokines, Type C Phospholipases, Protein Kinase C, Signal Transduction, Endothelial Growth Factors, DNA, Antisense, Phosphotransferases (Alcohol Group Acceptor), Phosphotyrosine, Phosphatidylinositol 3-Kinases, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Phospholipase C gamma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.